Succinic semialdehyde dehydrogenase deficiency in children and adults

Annals of Neurology

Volumn 54, Issue SUPPL. 6, 2003, Pages

  Pearl, Phillip L ^a,e   Novomy, Edward J ^b   Acosta, Maria T ^a   Jakobs, Cornelis ^c   Gibson, K Michael ^d  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 4 HYDROXYBUTYRIC ACID; 4,5 DIHYDROHEXANOIC ACID; 5 HYDROXYINDOLEACETIC ACID; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BIOGENIC AMINE; CARBAMAZEPINE; DOPAMINE; GLUTAMIC ACID; GLUTAMINE; HEXANOIC ACID DERIVATIVE; HOMOCARNOSINE; HOMOVANILLIC ACID; LAMOTRIGINE; NALOXONE; NCS 382; NEUROTRANSMITTER; OPIATE ANTAGONIST; SEROTONIN; SUCCINATE SEMIALDEHYDE DEHYDROGENASE; SUCCINIC SEMIALDEHYDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN;

4 AMINOBUTYRIC ACID METABOLISM; ABSENCE; ATAXIA; BEHAVIOR DISORDER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONFERENCE PAPER; DENTATE NUCLEUS; DEVELOPMENTAL DISORDER; DIAGNOSTIC IMAGING; ELECTROENCEPHALOGRAM; ENZYME ASSAY; ENZYME DEFICIENCY; EPILEPTIC DISCHARGE; EPILEPTIC STATE; EYE TOXICITY; GENE MUTATION; GLOBUS PALLIDUS; GRAND MAL EPILEPSY; HUMAN; INBORN ERROR OF METABOLISM; LABORATORY TEST; LANGUAGE DISABILITY; LEUKOCYTE; MENTAL DEFICIENCY; METABOLITE; MUSCLE HYPOTONIA; MYOCLONUS SEIZURE; NEUROPHYSIOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; RETINA DISEASE; SEIZURE; SUCCINATE SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; URINALYSIS; URINE LEVEL; WHITE MATTER;

ADULT; ALDEHYDE OXIDOREDUCTASES; AMINO ACID METABOLISM, INBORN ERRORS; BRAIN; CHILD; ELECTROENCEPHALOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING; SUCCINATE-SEMIALDEHYDE DEHYDROGENASE;

EID: 0041365682     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10629     Document Type: Conference Paper

References (47)

1. Gibson KM, Jansen I, Sweetman L, et al. 4-Hydroxybutyric aciduria. III. Enzymology and inheritance. J Inher Metab Dis 1984;7:95-96.
2. Bernasconi R, Mathivet P, Bischoff S, Marescaux C. Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential? Trends Pharmacol Sci 1999;20:135-141.
3. Gibson KM, Hoffman GF, Hodson AK, et al. 4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism. Neuropediatrics 1998;29:14-22.
4. Pearl PL, Gibson KM, Acosta MT, et al. Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 2003;60:1413-1417.
5. Trettel F, Malaspina P, Jodice C, et al. Human succinic semialdehyde dehydrogenase: molecular cloning and chromosomal localization. Adv Exp Med Biol 1997;414:253-260.
6. Gibson KM, Jakobs C. Disorders of beta- and gamma-amino acids in free and peptide-linked forms. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th edition. New York: McGraw-Hill, 2001:2079-2105.
7. Jakobs C, Bojasch M, Monch E, et al. Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities: the probability of a new inborn error of metabolism. Clin Chim Acta 1981;111:169-178.
8. Jakobs C, Jaeken J, Gibson KM. Inherited disorders of GABA metabolism. J Inher Metab Dis 1993;16:704-715.
9. Hodson AK, Gibson KM, Jakobs C. Developmental resolution of ataxia in succinic semialdehyde dehydrogenase deficiency. Ann Neurol 1990:28:438.
10. Gibson KM, Christensen E, Jakobs C, et al. The clinical phenotype of SSADH deficiency: case reports of 23 new patients. Pediatrics 1997;99:567-574.
11. Yalcinkaya C, Gibson KM, Gunduz E, et al. MRI findings in succinic semialdehyde dehydrogenase deficiency. Neuropediatrics 2000;31:45-46.
12. Al-Essa MA, Bakheet SM, Patay ZJ, et al. Clinical, FDG PET, MRI of the brain and biochemical observations in a patient with 4-hydroxybutyric aciduria: a progressive neurometabolic disease. Brain Dev 2000;22:127-131.
13. Ishiguro Y, Kajita M, Aoshima T, et al. The first case of 4-hydroxybutyric aciduria in Japan. Brain Dev 2001;23:128-130.
14. Onkenhout W, Maaswinkel-Mooij PD, Poorthuis BJ. 4-Hydroxybutyric aciduria: further clinical heterogeneity in a new case. Eur J Pediatr 1989;149:194-196.
15. Rahbeeni A, Ozand PT, Rashed M, et al. 4-Hydroxybutyric aciduria. Brain Dev 1994;16:S64-S71.
16. Gibson KM, Doskey AE, Rabier D, et al. Differing clinical presentation of succinic semialdehyde dehydrogenase deficiency in adolescent siblings from Lifu Island, New Cladedonia. J Inherit Metab Dis 1997;20:270-274.
17. Gibson KM, Hoffman G, Nyhan WL, et al. 4-Hydroxybutyric aciduria in a patient without ataxia or convulsions. Eur J Pediatr 1988;147:529-531.
18. Gibson KM, Goodman SI, Frerman FE, Glasgow AM. Succinic semialdehyde dehydrogenase deficiency associated with combined 4-hydroxybutyric and dicarboxylic acidurias: potential for clinical misdiagnosis based on urinary organic acid profiling. J Pediatr 1989;114:607-610.
19. Gibson KM, DeVivo DC, Jakobs C. Vigabatrin therapy in a patient with succinic semialdehyde dehydrogenase deficiency. Lancet 1989;2(8671):1105-1106.
20. Jakobs C, Smit LME, Kneer J, et al. The first adult case with 4-hydroxybutyric aciduria. J Inherit Metab Dis 1990;13:341-344.
21. Jakobs C, Michael T, Jaeger E, et al. Further evaluation of vigabatrin therapy in 4-hydroxybutyric aciduria. Eur J Pediatr 1992;151:466.
22. Matern D, Lehnert W, Gibson KM, Korinthenberg R. Seizures in a boy with SSADH deficiency treated with vigabatrin (gamma-vinyl-GABA). J Inher Metab Dis 1996;19:313-318.
23. Uziel G, Bardelli P, Pantaleoni C, et al. 4-Hydroxybutryic aciduria: clinical findings and vigabatrin therapy. J Inher Metab Dis 1993;16:520-522.
24. Howells DW, Jakobs C, Kok R, et al. Vigabatrin therapy in succinic semialdehyde dehydrogenase deficiency. Molecular Neuropharmacol 1992;2:181-184.
25. Jaeken J, Casaer P, deCopck P, Francois B. Vigabatrin in GABA metabolism disorders. Lancet 1989;1:1074 (Letter).
26. Dietz B, Aguigah G, Witting W, Aksu F. Vigabatrin-Therapie bei einem 7 jahrigen Jungen mit Succinat-Semialdehyd-Dehydrogenase Mangel. Monatsschr Kinderheilkd 1994;142:762 (Abstract).
27. Gibson KM, Schor DS, Gupta M, et al. Focal neurometabolic alterations in mice deficient for succinate semiadlehyde dehydrogenase. J Neurochem 2002;81:71-79.
28. Ziyeh S, Berlis A, Korinthenberg R, et al. Selective involvement of the globus pallidus and dentate nucleus in succinic semialdehyde dehydrogenase activity. Pediatr Radiol 2002;32:598-600.
29. Novotny EJ, de Graaf R, Mason G, Appel M, Gibson KM, Pearl P, Rothman DC. Brain GABA in SSADH Deficiency. (Abstract #1297). International Society of Magnetic Resonance in Medicine 11th Scientific Meeting and Exhibition. Toronto, Ontario, Canada, 7/10-16, 2003.
30. Brismar J, Ozand PT. CT and MR of the brain in disorders of the proprionate and methylmalonate metabolism. Am J Neuroradiol 1994;15:1459-1473.
31. Bonham JR, Downing M, Pollitt RJ et al. Quality assessment of urinary organic acid analysis. Ann Clin Biochem 1994;31:129-133.
32. Gibson KM, Aramaki S, Sweetman L, et al. Stable isotope dilution analysis of 4-hydroxybutyric acid: an accurate method for quantification in physiological fluids and the prenatal diagnosis of 4-hydroxybutyric aciduria. Biomed Environ Mass Spectrom 1990;19:89-93.
33. Brown GK, Bromby CH, Manning NJ, Pollitt RJ. Urinary organic acids in succinic semialdehyde dehydrogenase deficiency: evidence of alpha-oxidation of 4-hydroxybutyric acid, interaction of succinic semialdehyde with pyruvate dehydrogenase and possible secondary inhibition of mitochondrial beta-oxidation. J Inher Metab Dis 1987:10:367-375.
34. Pattarelli PP, Nyhan WL, Gibson KM. Oxidation of [U14C] succinic semialdehyde in cultured human lymphoblasts: measurement of residual succinic semialdehyde dehydrogenase activity in 11 patients with 4-hydroxybutyric aciduria. Pediatr Res 1988;24:455-460.
35. Gibson KM, Gupta M, Pearl PL, et al. Significant behavioral disturbances in SSADH deficiency (gamma-hydroxybutyric aciduria). Biol Psych (in press).
36. Maitre M. The GHB signaling system in brain: organization and functional implications. Prog Neurobiol 1997;51:337-361.
37. Maitre M, Andriamampandry C, Kemmel V, et al. Gamma-hydroxybutyric acid as a signaling molecule in brain. Alcohol 2000;20:277-283.
38. 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am J Psychiatry 1999;156:952-954.
39. Sonnewald U, McKenna M. Metabolic compartmentation in cortical synaptosomes: influence of glucose and preferential incorporation of endogenous glutamate into GABA. Neurochem Res 2002;27:43-50.
40. Gibson KM, Jakobs C, Ogier H, et al. Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis 1995;18:143-146.
41. Gross-Tsur V, Banin E, Shahar E, et al. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 2000;48:60-64.
42. Malmgren K, Ben-Menachem E, Frisen L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001;42:609-615.
43. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:614-618.
44. Hogema BM, Gupta M, Senephansiri H, et al. Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. Nat. Genet. 2001;29:212-216.
45. Gupta M, Greven R, Jansen EEW, et al. Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). J Pharmacol Exp Ther 2002;302:1-8.
46. Feigenbaum JJ, Howard SG. Naloxone reverses the inhibitory effect of gamma-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis study. Neurosci Lett 1997;224:71-74.
47. Anderson D, Bottiglieri T, Gibson KM. Pargyline antagonizes the effect of gamma-hydroxybutyrate (GHB) on locomotor activity in the rat (Abstract). Paper presented at: Society for Neuroscience 32nd Annual Meeting; 2002; Orlando, FL. [Program No. 749.15. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2002. Online.]